CMChristina Mary Mariaselvam

Christina Mary Mariaselvam

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christina Mary Mariaselvam has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Antiphospholipid antibody trajectories and clinical correlates in an inception cohort of systemic lupus erythematosus

    by Ritesh Kumar Mishra, Chengappa Kavadichanda, Priyanka Baskaran, Subin Philip, Rizwana Naushad, Sriyanka Mohapatra, Mani Rajendran, Kalaichelvi Kalidass, Aishwarya Gopal, Christina Mary Mariaselvam, et al.

    Objective: To evaluate longitudinal antiphospholipid antibody (aPL) patterns in newly diagnosed systemic lupus erythematosus (SLE) and their association with vascular events, disease activity and organ damage. Methods: We conducted a prospective study within the INSPIRE registry including patients with newly diagnosed SLE (median disease duration 232 days [114–484]) with serum at baseline, 6 and 24 months. Anti-cardiolipin (aCL) and anti-β2-glycoprotein I (anti-β2GPI) IgG/IgM were measured by ELISA, and lupus anticoagulant when feasible. aPL positivity was analysed using manufacturer cut-offs and moderate–high titres (>40 U). Patients were classified as persistently negative, positive, fluctuating or negativized. High- and low-risk aPL profiles were defined per EULAR recommendations. Associations with thrombosis, SLEDAI-2K, Physician Global Assessment (PGA) and SLICC/ACR Damage Index (SDI) were assessed. Results: Among 270 patients, 77.1% were aPL positive at least once, predominantly low-titre. Moderate–high titre aPLs were less frequent and stable. Most patients with baseline negativity or low-titre/single positivity reverted to negative, whereas dual or triple positivity was associated with persistence. A subgroup (3.1%) progressed from negative/low-titre to high-risk profiles. aPL negativization occurred in 12.5% and was inversely associated with baseline aPL burden. Over 2 years, 19 (7%) developed thrombosis, with higher risk in high-risk and persistently positive groups; no thrombotic events occurred in persistently aPL-negative patients. aPL titres did not correlate with SLEDAI-2K or PGA, while aCL IgG and anti-β2GPI IgG correlated weakly with anti-dsDNA. SDI remained low across groups. Conclusion: In early SLE, aPLs are largely low-titre and fluctuating, with some patients evolving to higher-risk states, supporting serial aPL testing.

  • Characterization of a 40-kDa pectin methylesterase as a candidate pollen allergen from Parthenium hysterophorus

    by Sreenivasulu Reddy Boreddy, Christina Mary Mariaselvam, Sathya Babu, Mahesh Padukudru Anand, Thirumurthy Madhavan, Vir Singh Negi

  • Immunosuppressant withdrawal versus glucocorticoid withdrawal in SLE: 2-year outcomes of a noninferiority randomized controlled trial

    by Aishwarya Gopal, Chengappa Kavadichanda, Christina Mary Mariaselvam, K T Harichandrakumar, Molly Mary Thabah, Vir Singh Negi

    Objectives: This study aimed to test whether immunosuppressant (IS) withdrawal is noninferior to glucocorticoid (GC) withdrawal in patients with SLE in remission. Methods: In this open-label, single-centre, randomized (1:1) controlled trial, we compared flare occurrence in stable SLE patients undergoing GC or IS tapering. Patients aged >18, on stable GC (prednisolone ≤7.5 mg/day) and maintenance non-biological IS for ≥3 years, in clinical remission for ≥1 year, were enrolled and assigned to taper GC or IS over 3 months. The primary endpoint was the proportion of patients experiencing a flare, defined by the SELENA-SLEDAI Flare Index (SFI) at 52 weeks. Patients in remission beyond 52 weeks were followed up to the maximum available follow-up duration beyond 104 weeks. Results: Between May and December 2021, 121 patients were randomized, and 117 (GC withdrawal, n = 58; IS withdrawal, n = 59) were included in the primary analysis. Flare occurred in 31% of the GC withdrawal group and 20.3% in the IS withdrawal group (risk difference, –10.6% [95% CI, −26.5 to 5.1]; P = 0.18), demonstrating the noninferiority of IS withdrawal. At maximum follow-up, 44.8% in the GC withdrawal group and 32.2% in the IS withdrawal group experienced a flare (risk difference, −12.6% [95% CI, −30.1 to 4.9]; P = 0.11), confirming the noninferiority of IS withdrawal at 2 years. Damage accrual was similar between the two groups at both endpoints. Conclusion: IS withdrawal is noninferior to GC withdrawal in SLE patients in long-term clinical remission. Personalized tapering strategies based on baseline damage and steroid exposure may optimize outcomes. Trial registration: The trial was registered with https://ctri.nic.in/, CTRI/2020/07/026712.


  • Open Access

    Role of Galectin-9, CXCL-10, APRIL, TNFRII and BAFF as Biomarkers in Idiopathic Inflammatory Myopathy: A Longitudinal Cohort Study

    by Saikumar Dunga, Aishwarya Gopal, Christina Mary Mariaselvam, Prakash Babu, Molly Mary Thabah, Vir Singh Negi, Chengappa Kavadichanda

    Objective: The study aimed to evaluate serum biomarkers (Galectin-9, TNFRII, APRIL, CXCL10, and BAFF) for their utility in identifying disease activity in idiopathic inflammatory myopathies (IIM) Methods: We enrolled adult patients who satisfied the 2017 EULAR/ACR criteria for IIM and categorised them into active (n = 16) and inactive (n = 24) subgroups. Inactive disease was defined as the absence of global and extramuscular activity, stable manual muscle testing 8 (MMT-8), and normal muscle enzymes over at least 6 months. We measured serum biomarkers by enzyme-linked immunosorbent assay (ELISA) at baseline, 3 and 6 months. We employed Spearman’s correlation, ROC curves, and multiple linear regression for evaluation. Results: We included 40 patients (mean age 38 ± 10 years; median disease duration 27.5 months). The majority had dermatomyositis (DM) (62.5%), followed by anti-synthetase syndrome (ASSD) (27.5%) and polymyositis (10%). Galectin-9, APRIL, and TNFRII levels were significantly higher in active disease ( P < .05). Galectin-9 demonstrated a modest correlation with MMT-8 changes (r = 0.534). A combination of Galectin-9, TNFRII, APRIL and creatine kinase (CK) levels showed the highest ROC AUC (0.953) to detect active disease. During the study, four patients initially categorised as ‘inactive’ patients exhibited improvement of 10% in MMT-8 over 6 months. To enhance sensitivity for detecting these clinically active diseases, we assessed Galectin-9 at lower cut-offs. Levels of 1146 pg/mL and 1109 pg/mL improved sensitivity to identify active disease to 81% and 87%, respectively, without compromising specificity. Conclusion: Serum biomarkers, Galectin-9, TNFRII, and APRIL, may help in differentiating between active and inactive disease in adult IIM. Notably, persistently elevated Galectin-9 levels, even in clinically quiescent disease, may signify ongoing activity.

  • Type I interferon gene expression signature as a marker to predict response to cyclophosphamide based treatment in proliferative lupus nephritis

    by Sree Nethra Bulusu, Christina Mary Mariaselvam, Sanket Shah, Vallayyachari Kommoju, Chengappa Kavadichanda, Kotten Thazhath Harichandrakumar, Molly Thabah, Vir Singh Negi

    Objectives: To assess the longitudinal effect of cyclophosphamide (CYC) treatment on type-I interferon (IFN) signature in proliferative lupus nephritis (LN) and its role in predicting treatment response. Methods: Fifty-four biopsy proven proliferative LN patients scheduled to receive high-dose (HD) or low-dose (LD) CYC were recruited and followed up for six months. At six months, patients were classified as clinical responders (CR) or non-responders (NR) to treatment, using the EULAR/EDTA criteria. An IFN-gene based score (IGS) was developed from the mean log-transformed gene expression of MX1, OAS1, IFIT1, OASL, IFIT4, LY6E, IRF7 at baseline, three and six months. Longitudinal changes of IGS within and between groups were assessed and ΔIGS, which is the difference in IGS between baseline and three months was calculated. Independent predictors of non-response were identified and an ROC analysis was performed to evaluate their utility to predict NR. Results: There was a dynamic change in IGS within the HD, LD, CR, and NR groups. Compared to baseline, there was a significant decrease in IGS at three months in HD and LD groups (HD group: 2.01 to 1.14, p = .001; LD group = 2.01 to 0.81, p < .001), followed by a significant increase from three to six months in LD group (LD: 0.81 to 1.51, p = .03; HD: 1.14 to 1.54, p = .300). A decrease in IGS from baseline to three months was seen in both CR (2.13 to 0.79, p < .001) and NR groups (1.83 to 1.27, p = .046), and a significant increase from three to six months was observed only in the CR group (CR: 0.79 to 1.57, p = .006; NR: 1.27 to 1.46, p = 1). ΔIGS (baseline to three months) was higher in CR compared to NR group (−1.339 vs −0.563, p = .017). ROC analysis showed that the model comprising of 0.81 fold decrease in IGS from baseline to three months, endocapillary hypercellularity and interstitial inflammation on renal histopathology predicted non-response with a sensitivity of 83.3% and specificity of 71.4%. Conclusion: In proliferative LN, treated with HD or LD-CYC, combined model comprising of decrease in IGS score by 0.81 fold from baseline to three months, along with important histopathological features such as endocapillary hypercellularity and interstitial inflammation had better predictive capability for non-response.


  • Low C4A copy numbers and higher HERV gene insertion contributes to increased risk of SLE, with absence of association with disease phenotype and disease activity

    by Christina Mary Mariaselvam, Gaurav Seth, Chengappa Kavadichanda, Wahid Boukouaci, Ching-Lien Wu, Bruno Costes, Molly Mary Thabah, Rajagopal Krishnamoorthy, Marion Leboyer, Vir Singh Negi, et al.

    Low copy numbers (CNs) of C4 genes are associated with systemic autoimmune disorders and affects autoantibody diversity and disease subgroups. The primary objective of this study was to characterize diversity of complement (C4) and C4-Human Endogenous Retrovirus (HERV) gene copy numbers in SLE. We also sought to assess the association of C4 and C4-HERV CNs with serum complement levels, autoantibodies, disease phenotypes and activity. Finally, we checked the association of C4 and HERV CNs with specific HLA alleles. Genomic DNA from 70 SLE and 90 healthy controls of south Indian Tamil origin were included. Demographic, clinical and serological data was collected in a predetermined proforma. CNs of C4A and C4B genes and the frequency of insertion of 6.4kb HERV within C4 gene (C4AL, C4BL) was determined using droplet digital polymerase chain reaction (ddPCR). A four digit high resolution HLA genotyping was done using next generation sequencing. In our cohort, the total C4 gene copies ranged from 2 to 6. Compared to controls, presence of two or less copies of C4A gene was associated with SLE risk (p = 0.005; OR = 2.79; 95% CI = 1.29–6.22). Higher frequency of HERV insertion in C4A than in C4B increases such risk (p = 0.000; OR = 12.67; 95% CI = 2.80-115.3). AL-AL-AL-BS genotype was significantly higher in controls than SLE (9%vs1%, p = 0.04; OR = 0.15, 95% CI = 0.00-0.16). Distribution of HLA alleles was not different in SLE compared to controls as well as in SLE subjects with ≤ 2 copies and > 2 copies of C4A, but HLA allele distribution was diverse in subjects with C4B ≤ 2 copies and > 2 copies. Finally, there was no correlation between the C4 and the C4-HERV diversity and complement levels, autoantibodies, disease phenotypes and activity. In conclusion, our data show that, low C4A copy number and higher insertion of HERV-K in C4A increases the risk for SLE. C4 and C4-HERV CNs did not correlate with serum complements, autoantibodies, disease phenotypes and activity in SLE. Further validation in a larger homogenous SLE cohort is needed.


  • Conventional Tregs in treatment-naïve rheumatoid arthritis are deficient in suppressive function with an increase in percentage of CXCR3 and CCR6 expressing Tregs

    by Vallayyachari Kommoju, Christina Mary Mariaselvam, Sree Nethra Bulusu, Chengappa Kavadichanda Ganapathy, Prakash Babu Narasimhan, Molly Mary Thabah, Vir Singh Negi

    In rheumatoid arthritis (RA), immune homeostasis is maintained by T regulatory cells (Tregs) that in an inflammatory milieu can change towards T-helper-like phenotypes (Th-like Tregs). Our aim was to examine the phenotypic and functional characteristics of CD4+CD25+CD127lo/− Tregs, Th-like Tregs and T effector (Teff) cells in the peripheral blood (PB) and synovial fluid (SF) of treatment-naïve early RA, as compared to osteoarthritis (OA) and healthy control (HC) peripheral blood. Frequencies of Tregs, CXCR3, CCR6 expressing Tregs (Th-like Tregs), and Teff cells were analyzed using flow cytometry in RA (n = 80), OA (n = 20), and HC (n = 40). Cytokine concentrations of the respective T cell subsets in plasma and SF were measured using flow cytometric bead array. Tregs sorted from RA and HC PB using magnetic beads were analyzed for functional capacities by CFSE proliferation assay and FOXP3 gene expression using real-time PCR. We observed that the frequencies of Th17 cells in PB and SF were significantly higher in RA when compared to HC, whereas Tregs were lower in PB and high in SF compared to HC and OA respectively. Th1- and Th17-related pro-inflammatory cytokines IL12p70, INF-γ, TNF-α, and IL-6, and IL-17A were significantly higher in the plasma and SF of RA. Tregs expressing CXCR3 (Th1-like Tregs) and CCR6 (Th17-like Treg) were significantly higher in PB and SF of RA compared to controls and was positively associated with seropositivity and disease activity. Treg cells isolated from peripheral blood of RA showed decreased function and reduced FOXP3 gene expression compared to HC. In our study, we have demonstrated higher frequencies of Th1 and Th17 cells and increased circulatory and SF pro-inflammatory cytokines (IL12P70, INF-γ, IL-6, IL-17A, and TNF-α) in RA. This inflammatory milieu might alter total Tregs frequencies and influence conversion of Tregs into Th-like Tregs.


  • Kidney histopathology in predicting flares following drug withdrawal in proliferative lupus nephritis in clinical remission

    by Aishwarya Gopal, Chengappa Kavadichanda, Mohan Sreelekha Gayathri, Mamatha Gorijavolu, Devender Bairwa, Christina Mary Mariaselvam, Bheemanathi Hanuman Srinivas, Molly Mary Thabah, Vir Singh Negi

    Residual renal histopathological activity at clinical remission in Proliferative Lupus Nephritis (PLN) can predict renal flare upon immunosuppression withdrawal. Data on the role of histological renal remission in predicting extra-renal flares is lacking. We assessed renal histopathology prior to drug withdrawal and the occurrence of renal and extra-renal flares over 52 weeks after drug withdrawal in PLN patients in long-term clinical remission. This is a subgroup analysis of a non-inferiority, open-label randomized (1:1) controlled trial. Patients with biopsy-proven Class III/IV LN in the past (biopsy 1), on immunosuppressants (IS) ≥ 3 years, in clinical remission for ≥ 1 year, on stable prednisolone dose (≤ 7.5 mg/day) plus a maintenance IS and hydroxychloroquine (HCQ) were subjected to a repeat renal biopsy (biopsy 2). Individuals with biopsy 2 having activity index (AI) < 4/24 were randomised to either prednisolone or IS withdrawal. Primary end-point was the proportion experiencing a flare [SELENA-SLEDAI flare index (SFI)] at week 52. Twenty-eight eligible patients underwent biopsy 2 and randomized to prednisolone (n = 15) and IS (n = 13) withdrawal. At biopsy 1, 12 (43%) had class III, 15 (53.5%) had class IV, and 1 (3.5%) had class III + V. At biopsy 2, PLN persisted in 4 (14.2%) while 18 (64.2%) were in histological remission (AI = 0) with 6 (21.4%) in class II. Following drug withdrawal, 9/28 (32%) had flares especially musculoskeletal (55.5%), mucocutaneous (44.4%), and renal (33.3%). Among the four persistent PLN patients, one of the two (50%) with AI = 1 had extra-renal flare while both the two with AI = 2 (100%) had renal and extra-renal flares. In those with histological remission (biopsy 2), 6/18 (66.6%) experienced extra-renal flare of whom one also had renal flare. Upon drug withdrawal, renal histopathology findings with any activity index can predict renal flare while histological remission is not enough to predict extra-renal flare, thus making it an unsuitable marker for deep SLE remission.


  • Synovial‐fluid‐derived microparticles express vimentin and GRP78 in their surface and exhibit an in vitro stimulatory effect on fibroblast‐like synoviocytes in rheumatoid arthritis

    by Benita Nancy Reni Michael, Christina Mary Mariaselvam, Chengappa G. Kavadichanda, Vir Singh Negi

    Objectives: To investigate the hypothesis that microparticles (MP) may be a source of autoantigens and drive disease progression in rheumatoid arthritis (RA) synovium.Methods: Synovial fluid (SF) was collected from the knee joints of 41 disease‐modifying anti‐rheumatic drug‐naive RA patients and 30 osteoarthritis (OA) patients. Samples were stained with either anti‐vimentin‐AlexaFluor‐488 or anti‐glucose‐regulated protein‐78‐Dylight‐488 (GRP78) and Annexin‐V‐allophycocyanin for flow cytometry analysis. RA and OA fibroblast‐like synoviocytes (FLS) were co‐cultured with respective SF‐derived MP in vitro for 24 h. Supernatant and cell‐free SF was assayed for pro‐inflammatory analytes by multiplex assays.Results: Elevated percentages of AnnexinV+ Vimentin+ MP (median 0.8, interquartile range [IQR] 1.30) and AnnexinV+ GRP78+ MP (median 0.3, IQR 0.28) were present in RA compared with OA patients. We observed that CXCL6 and CCL8 were secreted in excess by RA‐FLS stimulated with RA‐SF‐MP but not by stimulation with MP‐free RA‐SF.Conclusions: Microparticles express vimentin and GRP78 on their surface and stimulate synoviocytes to produce inflammatory molecules, thus sustaining local inflammation in the synovium in RA.